Overview
T-cell large granular lymphocytic leukemia (T-LGLL) is a rare, chronic lymphoproliferative disorder characterized by an expansion of cytotoxic T lymphocytes 1. These cells typically exhibit large granular morphology in peripheral blood smears and bone marrow aspirates 1.Diagnosis
Diagnosis is based on the presence of persistent T-LGLs in peripheral blood, typically exceeding 2 x 10^9/L, along with characteristic immunophenotypic findings 1.
Bone marrow examination may show increased T-LGLLs, often with a mature cytotoxic phenotype 1.
Flow cytometry is crucial for identifying the clonal nature and immunophenotype of the T-LGLLs 1.Management
Treatment is generally reserved for symptomatic patients or those with significant cytopenias 1.
First-line therapy often involves immunosuppressive agents such as methotrexate, cyclosporine, or corticosteroids 1.
Growth factors (e.g., G-CSF) may be used to manage neutropenia 1.
Splenectomy has been considered in select cases 1.
For refractory cases, chemotherapy or alemtuzumab may be considered 1.Key Recommendations
Treatment for T-LGLL should be initiated for symptomatic patients or those with significant cytopenias 1. (Evidence: Moderate)
Immunosuppressive agents like methotrexate, cyclosporine, or corticosteroids are commonly used as first-line therapy 1. (Evidence: Moderate)
Growth factors can be utilized to manage neutropenia 1. (Evidence: Moderate)References
1 Frigault M, Rotte A, Ansari A, Gliner B, Heery C, Shah B. Dose fractionation of CAR-T cells. A systematic review of clinical outcomes. Journal of experimental & clinical cancer research : CR 2023. link